Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. This is in addition to its long-available pneumococcal polysaccharide vaccine PPSV23.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

pharmaphorum

DECEMBER 4, 2020

Valneva has said it plans to accelerate research into its Lyme disease vaccine candidate VLA15, bringing forward a trial including children into the first quarter of 2021. Pfizer will pay up to $45 million in development related milestone payments and up to $143 million if the vaccine hits early sales targets.

Vaccination 117

Vaccination Vaccine Bacterium Protein 117

XTalks

JULY 28, 2021

Merck has scored US Food and Drug Administration (FDA) approval for its next-generation pneumonia vaccine Vaxneuvance that covers 15 different strains of the pneumococcal bacteria that causes the infection. Compared to Vaxneuvance’s targeting of 15 different strains of the bacterium, Pfizer’s shot protects against 20.

FDA Approval 89

FDA Approval Vaccination Vaccine Immune Response 89

pharmaphorum

MARCH 2, 2022

Pfizer’s vaccine for Clostridium difficile (C. Top-line efficacy for the vaccine was 49% at 12 months, 47% at 24 months and 31% at final analysis, said the drugmaker, which was forced to carry out the assessment after 42 cases of CDI, fewer than the 66 cases laid out in the trial protocol. With no approved vaccines to date, C.

Vaccination 52

Vaccination Vaccine Trials Bacterium 52

pharmaphorum

MAY 31, 2022

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. billion in sales last year. billion in sales last year. GlaxoSmithKline has agreed a $3.3 GSK said it is paying $2.1

Vaccination 52

Vaccination Vaccine Bacterium Sales 52

XTalks

AUGUST 2, 2023

With each passing year, pharmaceutical companies around the globe strive to deliver cutting-edge medicines, therapies and vaccines that impact the lives of millions. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. Pfizer’s total global revenue from the Prevnar family of vaccines was $6.34

Sales 98

Sales Manufacturing FDA Approval Life Science 98

pharmaphorum

JULY 14, 2021

Already facing one rival to its blockbuster pneumococcal vaccine Prevnar, Pfizer could have another to contend with, after Affinivax reported positive phase 2 results with its ASP3772 candidate – plus a new breakthrough designation from the FDA. That is equivalent to 14% of Pfizer’s total revenues.

Immune Response 52

Immune Response Vaccination Vaccine Protein 52